Axis-Shield
Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.
Bio-Rad Takes Option to Commercialize Axis-Shield's HBP Sepsis Marker
Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.
FDA Clears Rheumatoid Dx Test by Bio-Rad, Axis-Shield
With FDA clearance, the test, which had been available outside the US, will now become available in the US.